CA2893981C - Chemokine-cytokine fusion protein and its use - Google Patents

Chemokine-cytokine fusion protein and its use Download PDF

Info

Publication number
CA2893981C
CA2893981C CA2893981A CA2893981A CA2893981C CA 2893981 C CA2893981 C CA 2893981C CA 2893981 A CA2893981 A CA 2893981A CA 2893981 A CA2893981 A CA 2893981A CA 2893981 C CA2893981 C CA 2893981C
Authority
CA
Canada
Prior art keywords
chemokine
polypeptide
fusion protein
cytokine
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2893981A
Other languages
English (en)
French (fr)
Other versions
CA2893981A1 (en
Inventor
Shiow-Her Chiou
Kuan-Chih Chow
Jui-Hung Shien
Yi-Hsin Fan
Pei-hua LIN
Pei-Shan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Chung Hsing University
Original Assignee
National Chung Hsing University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Chung Hsing University filed Critical National Chung Hsing University
Publication of CA2893981A1 publication Critical patent/CA2893981A1/en
Application granted granted Critical
Publication of CA2893981C publication Critical patent/CA2893981C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2893981A 2012-12-05 2012-12-05 Chemokine-cytokine fusion protein and its use Active CA2893981C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/001629 WO2014085947A1 (zh) 2012-12-05 2012-12-05 趋化素-细胞素融合蛋白和其应用

Publications (2)

Publication Number Publication Date
CA2893981A1 CA2893981A1 (en) 2014-06-12
CA2893981C true CA2893981C (en) 2021-11-16

Family

ID=50882722

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2893981A Active CA2893981C (en) 2012-12-05 2012-12-05 Chemokine-cytokine fusion protein and its use

Country Status (7)

Country Link
US (4) US20150307577A1 (enExample)
EP (1) EP2930189B1 (enExample)
JP (1) JP6174710B2 (enExample)
CN (1) CN104968686B (enExample)
AU (1) AU2012396113B2 (enExample)
CA (1) CA2893981C (enExample)
WO (1) WO2014085947A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
KR20240024781A (ko) * 2021-04-19 2024-02-26 워킹 피쉬 테라퓨틱스 인코포레이티드 세포 요법에 사용하기 위한 b 세포 확장의 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
CA2322687A1 (en) * 1999-10-29 2001-04-29 Regents Of The University Of California Compositions containing c-terminal polypeptides of angiogenic chemokines and methods of use
WO2001040311A1 (fr) * 1999-11-30 2001-06-07 Shionogi & Co., Ltd. Proteine fusionnee de chimiokine slc-il2
US20050053579A1 (en) * 2001-10-23 2005-03-10 Jacques Galipeau Novel synthetic chimeric fusion transgene with immuno-therapeutic uses
US20050287118A1 (en) * 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
CN101445560A (zh) * 2008-12-31 2009-06-03 河南省生物工程技术研究中心 一种畜禽用融合蛋白的制备方法

Also Published As

Publication number Publication date
US10336801B2 (en) 2019-07-02
US20150307577A1 (en) 2015-10-29
AU2012396113A1 (en) 2015-07-02
WO2014085947A1 (zh) 2014-06-12
US20190270788A1 (en) 2019-09-05
EP2930189A4 (en) 2016-06-08
CA2893981A1 (en) 2014-06-12
US20230265150A1 (en) 2023-08-24
EP2930189A1 (en) 2015-10-14
AU2012396113B2 (en) 2017-03-30
JP6174710B2 (ja) 2017-08-02
CN104968686B (zh) 2020-02-04
JP2016503434A (ja) 2016-02-04
US20170327554A1 (en) 2017-11-16
EP2930189B1 (en) 2020-04-29
CN104968686A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
US20230265150A1 (en) A fusion proteon of stromal cell-derived factor-1 (sdf-1) and interleukin-2 (il-2) and applications thereof
Li et al. The immunoregulation of Th17 in host against intracellular bacterial infection
Wang et al. First in-depth analysis of the novel Th2-type cytokines in salmonid fish reveals distinct patterns of expression and modulation but overlapping bioactivities
Secombes Will advances in fish immunology change vaccination strategies?
US20070160578A1 (en) Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
Chen et al. Enhancement of immune response of piglets to PCV-2 vaccine by porcine IL-2 and fusion IL-4/6 gene entrapped in chitosan nanoparticles
Kaur et al. Role of cytokines as immunomodulators
Sanchez et al. Expression of inducible CC chemokines in rainbow trout (Oncorhynchus mykiss) in response to a viral haemorrhagic septicemia virus (VHSV) DNA vaccine and interleukin 8
Van Belleghem et al. Phage interaction with the mammalian immune system
EP1730187A1 (en) Immunosuppressive cytokine
Rahman et al. Prospects and challenges of using chicken cytokines in disease prevention
Lin et al. The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs
Yan et al. Harnessing cytokines: innovative adjuvants for improved veterinary vaccine efficacy
TWI487713B (zh) 趨化素－細胞素融合蛋白和其應用
Abraham et al. Effects of therapy with soluble tumour necrosis factor receptor fusion protein on pulmonary cytokine expression and lung injury following haemorrhage and resuscitation
CN103232544A (zh) 一种重组猪干扰素γ-Fc融合蛋白及其编码基因和表达方法
Yu et al. Actin depolymerizing factor-based nanomaterials: a novel strategy to enhance E. mitis-specific immunity
WO2014172805A1 (zh) 具有增进的细胞素活性的组合物和其应用
Aru sion in of i
TW201441250A (zh) 具有增進的細胞素活性的組合物和其應用
Leader et al. Expression of rabbit interleukin-4 and characterization of its biologic activity on T and B-cells
Johnkennedy et al. Clinical Cardiovascular Research
Dechamma Certificate
KR20160069204A (ko) 인간 카텔리시딘 ll-37을 포함하는 면역 활성 유도제, 이를 포함한 경구 백신, 및 이를 이용한 면역 활성 유도 방법
US20240156934A1 (en) Compositions And Methods Of MAIT Cell Activation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160915

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260729